[1. M. D. Ezekowitz, Atrial fibrillation: the epidemic of the new millennium, Ann. Intern. Med. 131 (1999) 537-538; DOI: 10.7326/0003-4819-131-7-199910050-00011.10.7326/0003-4819-131-7-199910050-0001110507965]Search in Google Scholar
[2. A. S. Go, E. M. Hylek, K. A. Phillips, Y. Chang, L. E. Henault, J. V. Selby and D. E. Singer, Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) study, JAMA 285 (2001) 2370-2375; DOI: 10.1001/jama.285.18.2370.10.1001/jama.285.18.237011343485]Search in Google Scholar
[3. Y. Miyasaka, M. E. Barnes, B. J. Gersh, S. S. Cha, K. R. Bailey, W. P. Abhayaratna, J. B. Seward and T. S. M. Tsang, Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence, Circulation 114 (2006) 119-125; DOI: 10.1161/CIRCULATIONAHA.105.595140.10.1161/CIRCULATIONAHA.105.59514016818816]Search in Google Scholar
[4. M. Zoni-Berisso, A. Filippi, M. Landolina, O. Brignoli, G. D’Ambrosio, G. Maglia, M. Grimaldi and G. Ermini, Frequency, patient characteristics, treatment strategies, and resource usage of atrial fibrillation (from the Italian Survey of Atrial Fibrillation Management [ISAF] study), Am. J. Cardiol. 111 (2013) 705-711; DOI: 10.1016/j.amjcard.2012.11.026.10.1016/j.amjcard.2012.11.02623273528]Search in Google Scholar
[5. C. Bilato, M. C. Corti, G. Baggio, D. Rampazzo, A. Cutolo, S. Iliceto and G. Crepaldi, Prevalence, functional impact, and mortality of atrial fibrillation in an older Italian population (from the Pro.V.A. study), Am. J. Cardiol. 104 (2009) 1092-1097; DOI: 10.1016/j.amjcard.2009.05.058.10.1016/j.amjcard.2009.05.05819801031]Search in Google Scholar
[6. P. A. Wolf, R. D. Abbott and W. B. Kannell, Atrial fibrillation: a major contributor to stroke in the elderly: the Framingham study, Arch. Intern. Med. 147 (1987) 1561-1564; DOI: 10.1001/archinte.1987.00370090041008.10.1001/archinte.1987.00370090041008]Search in Google Scholar
[7. H. J. Lin, P. A. Wolf, M. Kelly-Hayes, A. S. Beiser, C. S. Kase, E. J. Benjamin and R. B. D’Agostino, Stroke severity in atrial fibrillation. The Framingham study, Stroke 27 (1996) 1760-1764; DOI: 10.1161/01.STR.27.10.1760.10.1161/01.STR.27.10.1760]Search in Google Scholar
[8. D. A. Dulli, H. Stanko and R. L. Levine, Atrial fibrillation is associated with severe acute ischemic stroke, Neuroepidemiology 22 (2003) 118-123; DOI: 10.1159/000068743.10.1159/00006874312629277]Search in Google Scholar
[9. M. Lamassa, A. Di Carlo, G. Pracucci, A. M. Basile, G. Trefoloni, P. Vanni, S. Spolveri, M. C. Baruffi, G. Landini, A. Ghetti, C. D. Wolfe and D. Inzitari, Characteristics, outcome, and care of stroke associated with atrial fibrillation in Europe: data from a multicenter multinational hospital-based registry (The European Community Stroke Project), Stroke 32 (2001) 392-398; 10.1161/01.STR.32.2.392.]Search in Google Scholar
[10. A. J. Camm, G. Y. Lip, R. De Caterina, I. Savelieva, D. Atar, S. H. Hohnloser, G. Hindricks, P. Kirchhof and ESC Committee for Practice Guidelines (CPG), 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association, Eur. Heart J. 33 (2012) 2719-2747; DOI: 10.1093/eurheartj/ehs253.10.1093/eurheartj/ehs25322922413]Search in Google Scholar
[11. A. Raviele, M. Disertori, P. Alboni, E. Betrtaglia, G. Botto, M. Brignole, R. Cappato, A. Capucci, M. Del Greco, R. De Ponti, M. Di Biase, G. Di Pasquale, M. Gulizia, F. Lombardi, S. Themistoclakis and M. Tritto, AIAC guidelines on the management and treatment of atrial fibrillation. Update 2013. Associazione Italiana di Aritmologia e Cardiostimolazione, Gior. Ital. Cardiol. (Rome) 14 (2013) 215-240; DOI: 10.1714/1234.13660.]Search in Google Scholar
[12. D. E. Singer, G. W. Albers, J. E. Dalen, A. S. Go, J. L. Halperin and W. J. Manning, Antithrombotic therapy in atrial fibrillation: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy, Chest 126 (Suppl. 3) (2004) 429S-456S; DOI: 10.1378/chest.126.3_suppl.429S.10.1378/chest.126.3_suppl.429S15383480]Search in Google Scholar
[13. I. M. Ogilvie, N. Newton, S. A. Welner, W. Cowell and G. Y. Lip, Underuse of oral anticoagulants in atrial fibrillation: a systematic review, Am. J. Med. 123 (2010) 638-645; DOI: 10.1016/j.amjmed.2009.11.025.10.1016/j.amjmed.2009.11.02520609686]Search in Google Scholar
[14. S. J. Connolly, J. Pogue, J. Eikelboom, G. Flaker, P. Commerford, M. G. Franzosi, J. S. Healey and S. Yusuf, ACTIVE W Investigators, Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range, Circulation 118 (2008) 2029-2037; DOI: 10.1161/CIRCULATIONAHA.107.750000.10.1161/CIRCULATIONAHA.107.75000018955670]Search in Google Scholar
[15. P. L. Hess, M. J. Mirro, H. C. Diener, J. W. Eikelboom, S. M. Al-Khatib, E. M. Hylek, H. B. Bosworth, B. J. Gersh, D. E. Singer, G. Flaker, J. L. Mega, E. D. Peterson, J. S. Rumsfeld, B. A. Steinberg, A. K. Kakkar, R. M. Califf and C. B. Granger, Atrial Fibrillation Think-Tank Participants, Addressing barriers to optimal oral anticoagulation use and persistence among patients with atrial fibrillation: Proceedings, Washington, DC, December 3-4, (2012), Am. Heart J. 168 (2014) 239-247; DOI: 10.1016/j.ahj.2014.04.007.10.1016/j.ahj.2014.04.007426955525173533]Search in Google Scholar
[16. M. Zalesak, K. Siu, K. Francis, C. Yu, H. Alvrtsyan, Y. Rao, D. Walker, S. Sander, G. Miyasato, D. Matchar and H. Sanchez, Higher persistence in newly diagnosed nonvalvular atrial fibrillation patients treated with dabigatran versus warfarin, Circ. Cardiovasc. Qual. Outcomes 6 (2013) 567-574; DOI: 10.1161/CIRCOUTCOMES.113.000192.10.1161/CIRCOUTCOMES.113.00019223922182]Search in Google Scholar
[17. S. Capizzi, M. L. Specchia, A. M. Ferriero, C. Cadeddu, A. Mancuso, C. De Waure, G. La Torre and G. Ricciardi, La gestione della TAO con i nuovi farmaci anticoagulanti orali: una nuova frontiera, in Rivaroxaban per la prevenzione dell’ictus in pazienti con fibrillazione atriale: risultati di una valutazione di HTA, Quaderni Ital. J. Pub. Health (QIJPH) 2 (2013) 80-104.]Search in Google Scholar
[18. C. T. January, L. S. Wann, J. S. Alpert, H. Calkins, J. E. Cigarroa, J. C. Cleveland, J. B. Conti, P. T. Ellinor, M. D. Ezekowitz, M. E. Field, K. T. Murray, R. L. Sacco, W. G. Stevenson, P. J. Tchou, C. M. Tracy and C. W. Yancy, 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: Executive summary. A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society, Circulation 130 (2014) 2071-2104; DOI: 10.1161/CIR.0000000000000040.10.1161/CIR.000000000000004024682348]Search in Google Scholar
[19. B. F. Gage, A. D. Waterman, W. Shannon, M. Boechler, M. W. Rich and M. J. Radford, Validation of clinical classification schemes for predicting stroke - Results from the National Registry of Atrial Fibrillation, JAMA 285 (2001) 2864-2870; DOI: 10.1001/jama.285.22.2864.10.1001/jama.285.22.286411401607]Search in Google Scholar
[20. M. Hughes and G. Y. Lip, Guideline Development Group, National Clinical Guideline for Management of Atrial Fibrillation in Primary and Secondary Care, National Institute for Health and Clinical Excellence, Stroke and thromboembolism in atrial fibrillation: a systematic review of stroke risk factors, risk stratification schema and cost effectiveness data, Thromb. Haemost. 99 (2008) 295-304; DOI: 10.1160/TH07-08-0508.10.1160/TH07-08-050818278178]Search in Google Scholar
[21. J. B. Olesen, C. Torp-Pedersen, M. L. Hansen and G. Y. Lip, The value of the CHA2DS2-VASC score for refining stroke risk stratification in patients with atrial fibrillation with a CHADS2 score 0-1: a nationwide cohort study, Thromb. Haemost. 107 (2012) 1172-1179; DOI: 10.1160/TH12-03-0175.10.1160/TH12-03-017522473219]Search in Google Scholar
[22. F. R. Rosendaal, S. C. Cannegieter, F. J. van der Meer and E. Briët, A method to determine the optimal intensity of oral anticoagulant therapy, Thromb. Haemost. 69 (1993) 236-239.10.1055/s-0038-1651587]Search in Google Scholar
[23. S. Barra and S. Fynn, Untreated atrial fibrillation in the United Kingdom: Understanding the barriers and treatment options, J. Saudi Heart Assoc. 27 (2015) 31-43; DOI: 10.1016/j.jsha.2014.08.002.10.1016/j.jsha.2014.08.002427431025544820]Search in Google Scholar
[24. E. C. O’Brien, D. N. Simon, L. A. Allen, D. E. Singer, G. C. Fonarow, P. R. Kowey, L. E. Thomas, M. D. Ezekowitz, K. W. Mahaffey, P. Chang, J. P. Piccini and E. D. Peterson, Reasons for warfarin discontinuation in the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF), Am. Heart J. 168 (2014) 487-494; DOI: 10.1016/j.ahj.2014.07.002.10.1016/j.ahj.2014.07.00225262258]Search in Google Scholar
[25. P. J. Zimetbau, A. Thosani, H. T. Yu, Y. Xiong, J. Lin, P. Kothawala and M. Emons, Are atrial fibrillation patients receiving warfarin in accordance with stroke risk?, Am. J. Med. 123 (2010) 446-453; DOI: 10.1016/j.amjmed.2009.11.015.10.1016/j.amjmed.2009.11.01520399322]Search in Google Scholar
[26. N. Mochalina, A. Jöud, M. Carlsson, M. E. Sandberg, A. Själander, T. Juhlin and P. J. Svensson, Antithrombotic therapy in patients with non-valvular atrial fibrillation in Southern Sweden: A population-based cohort study, Thromb. Res. 140 (2016) 94-99; DOI: 10.1016/j.thromres.2016.02.023.10.1016/j.thromres.2016.02.02326938155]Search in Google Scholar
[27. C. Sarawate, M. V. Sikirica, V. J. Willey, M. F. Bullano and O. Hauch. Monitoring anticoagulation in atrial fibrillation, J. Thromb. Thrombolysis 21 (2006) 191-198; DOI: 10.1007/s11239-006-4968-z.10.1007/s11239-006-4968-z16622617]Search in Google Scholar
[28. C. van Walraven, C. A. Jennings, N. Oake, D. Fergusson and A. J. Foster, Effect of study setting on anticoagulation control: a systematic review and metaregression, Chest 129 (2006) 1155-1166; DOI: 10.1378/chest.129.5.1155.10.1378/chest.129.5.115516685005]Search in Google Scholar